Contract Pharma2d
Nutriband and Kindeva to Co-Develop Aversa Fentanyl Abuse-Deterrent Patch
Aversa Fentanyl holds the potential to become the world’s first abuse-deterrent opioid patch.
Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments Nutriband is partnering with ...
Business Insider8d
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™
ORLANDO, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced ...
Yahoo Finance8d
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™
AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl ...
Nutriband partners with Kindeva for opioid patch development
ORLANDO - Nutriband Inc. (NASDAQ:NTRB), a developer of transdermal pharmaceutical products, has announced an exclusive partnership with Kindeva Drug Delivery to develop Aversa™ Fentanyl, a potential ...
Nasdaq8d
Nutriband Inc. Receives USPTO Notice of Allowance for Aversa™ Abuse Deterrent Transdermal Technology Patent
AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl ...
Investing8d
Nutriband secures US patent for abuse deterrent patch
such as opioids and stimulants. Nutriband's leading product in development, AVERSA™ Fentanyl, is an abuse deterrent fentanyl transdermal system. It is on track to potentially become the first ...